AstraZeneca COVID-19 vaccine likely to protect for a year - CEO
BRUSSELS (Reuters) - AstraZeneca's potential coronavirus vaccine <AZN.L> is expected to protect against COVID-19 infection for about a year, the company's managing director told a Belgian radio station on Tuesday.
The British pharmaceutical company has already started trials on people developed by Oxford University. A Phase I study in the UK is expected to end soon and a Phase III study has already started, Pascal Soriot told Bel RTL.
"We believe it will protect for about a year," said Soriot.
AstraZeneca announced on Saturday that it had signed contracts with France, Germany, Italy and the Netherlands for the delivery of up to 400 million doses of the potential vaccine to the European Union.
Agreements have also been made with the United Kingdom and the United States.
"If everything goes well, we will have the results of the clinical studies in August / September. We will produce in parallel. We will be able to deliver from October if everything goes well," said Soriot.
(Reporting by Philip Blenkinsop; Editing by Jason Neely)
Watch the latest videos from Yahoo UK
Click to receive the most important news as a notification!
A Handwritten Note from Princess Diana Claiming She Wasn't Manipulated Into Her BBC Interview Has Gone Missing
She taught fourth graders about Black Lives Matter. Parents demanded her firing.
This camper van rental company will let you subscribe to book RVs for months or even years at a time — see how it works
Graham Mertz and No. 14 Wisconsin rout Illinois, 45-7, in the Big Ten season opener
I'd Like to Know Where the Avengers' Energy For Speaking Out Was Before Twitter's Chris Discourse
This Is the Horror Villain Who Probably Still Haunts You, Research Shows